Coherus BioSciences - CHRS Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Coherus BioSciences in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CHRS shares.
View CHRS analyst ratings or view top-rated stocks.

4 brokers have issued 1 year price targets for Coherus BioSciences' shares. Their CHRS share price forecasts range from $7.00 to $30.00. On average, they expect the company's share price to reach $16.50 in the next year. This suggests a possible upside of 150.8% from the stock's current price.
View analysts price targets for CHRS or view top-rated stocks among Wall Street analysts.

Coherus BioSciences' stock was trading at $15.96 at the start of the year. Since then, CHRS stock has decreased by 58.8% and is now trading at $6.58.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 16th 2023.
View our CHRS earnings forecast.

Coherus BioSciences, Inc. (NASDAQ:CHRS) announced its quarterly earnings results on Sunday, November, 7th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by $0.12. The biotechnology company earned $82.50 million during the quarter, compared to the consensus estimate of $86.96 million. Coherus BioSciences had a negative trailing twelve-month return on equity of 422.10% and a negative net margin of 116.54%. During the same period last year, the business posted $0.33 earnings per share.

21 employees have rated Coherus BioSciences Chief Executive Officer Dennis M. Lanfear on Glassdoor.com. Dennis M. Lanfear has an approval rating of 95% among the company's employees. This puts Dennis M. Lanfear in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus BioSciences investors own include Halozyme Therapeutics (HALO), Chembio Diagnostics (CEMI), Exelixis (EXEL), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Intelsat (I), Idera Pharmaceuticals (IDRA), Immunomedics (IMMU), Sangamo Therapeutics (SGMO) and Viking Therapeutics (VKTX).

Coherus BioSciences trades on the NASDAQ under the ticker symbol "CHRS."

Coherus BioSciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (16.69%), Alliancebernstein L.P. (7.85%), Vanguard Group Inc. (6.72%), State Street Corp (6.56%), Disciplined Growth Investors Inc. MN (1.46%) and Peregrine Capital Management LLC (1.45%). Insiders that own company stock include Dennis M Lanfear, James Healy, Jean-Frederic Viret, Mary T Szela, Mats Wahlstrom, Mcdavid Stilwell, Vincent R Anicetti and Vladimir Vexler.
View institutional ownership trends.

Shares of CHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CHRS stock can currently be purchased for approximately $6.58.

Coherus BioSciences (NASDAQ:CHRS) has a market capitalization of $511.79 million and generates $326.55 million in revenue each year. The biotechnology company earns $-287,100,000.00 in net income (profit) each year or ($3.60) on an earnings per share basis.

The company employs 332 workers across the globe.

Coherus BioSciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The official website for the company is www.coherus.com. The biotechnology company can be reached via phone at (650) 649-3530 or via email at darrington@coherus.com.